Oncorus Announces Promotion of John Goldberg, M.D. to Chief Medical Officer
February 22 2022 - 8:00AM
Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company
focused on driving innovation to transform outcomes for cancer
patients, today announced the promotion of John Goldberg, M.D. to
Chief Medical Officer. Dr. Goldberg joined Oncorus in October 2018
as Senior Vice President of Clinical Development with
responsibilities including oversight of all clinical studies, drug
development and regulatory strategies.
“We are delighted to announce John’s promotion to
Chief Medical Officer as he has been an integral part of our
company’s progress thus far. His first-hand experience as a
practicing oncologist with over 15 years of experience enrolling
patients into clinical trials, coupled with expertise across a
range of immunotherapies, have been crucial to our pipeline
progress and we are incredibly pleased to have his continued
guidance in this new role,” said Theodore (Ted) Ashburn, M.D.,
Ph.D., President and Chief Executive Officer of Oncorus. “We look
forward to John’s leadership as we continue to advance our viral
immunotherapy candidate, ONCR-177, through the clinic with
additional data from multiple cohorts expected later this year, in
addition to progressing our ONCR-GBM program and selectively
self-amplifying viral RNA (vRNA) product candidates ONCR-021 and
ONCR-788.”
“It’s an honor to take on the role of Chief Medical
Officer at Oncorus, and I’m incredibly excited and motivated by the
unique opportunity that Oncorus has to make a meaningful difference
in cancer patients’ lives via its dual platform approach to
unleashing the full potential of viral immunotherapies,” said Dr.
Goldberg. “Both the HSV and selectively self-amplifying vRNA
platforms create a uniquely diverse pipeline rooted in compelling
science and promising future growth. I believe that Oncorus has the
potential to meaningfully impact the current standard of care in
oncology, and, in partnership with the rest of the executive team,
I look forward to advancing this innovative technology.”
Dr. Goldberg has served as Senior Vice President of
Clinical Development since he joined Oncorus in 2018. Prior to
joining Oncorus, Dr. Goldberg served as Senior Medical Director of
H3 Biomedicine, a developer of genomics-based cancer therapies.
While at H3 Biomedicine, he supervised the clinical development of
H3B-8800, the first-in-human spliceosome modulator. Previously, Dr.
Goldberg held clinical roles in cancer drug development, leading
the pediatric oncology Phase 1 program at the University of Miami
and working as Medical Director for Agenus. His immunotherapy
experience includes first-in-human neo-antigen vaccines, dendritic
cell vaccine and GVAX trials, as well as check point inhibitors and
costimulatory agonists. Dr. Goldberg is also a pediatric oncologist
with 15 years of experience treating children with cancer and
enrolling patients in clinical trials. He received his pediatric
hematology oncology training from the Dana-Farber Cancer Institute
and Children’s Hospital Boston and his general pediatrics training
from the University of Rochester. Dr. Goldberg holds an M.D. from
the University of Massachusetts Medical School and a A.B. in
Biological Sciences from the University of Chicago. In addition to
his current role at Oncorus, Dr. Goldberg is a Medical Advisory
Board Member for the Sarcoma Foundation of America and a member of
the Advisory Group at MassBio.
About OncorusAt Oncorus, we are
focused on driving innovation to deliver next-generation viral
immunotherapies to transform outcomes for cancer patients. We are
advancing a portfolio of intratumorally (iTu) and intravenously
(IV) administered viral immunotherapies for multiple indications
with significant unmet need based on our oncolytic Herpes Simplex
Virus (HSV) Platform and selectively self-amplifying viral RNA
(vRNA) Immunotherapy Platform.
Designed to deliver next-generation viral
immunotherapy impact, our HSV Platform improves upon key
characteristics of this therapeutic class to enhance systemic
activity. Our lead HSV program, ONCR-177, is designed to be
directly administered into a tumor, resulting in high local
concentrations of the therapeutic agent and its five encoded
transgenes, as well as low systemic exposure to the therapy, which
could limit systemic toxicities. Our pioneering selectively
self-amplifying vRNA Immunotherapy Platform involves a highly
innovative, novel combination of RNA- and oncolytic virus-based
modalities designed to realize the potential of RNA medicines for
cancer. Our lead IV-administered selectively self-amplifying vRNA
Immunotherapy clinical candidates, ONCR-021 and ONCR-788, are both
currently in IND-enabling studies.
Please visit www.oncorus.com to learn more.
Cautionary Note Regarding Forward-Looking
Statements
This press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995, as amended, including, without limitation,
implied and express statements regarding the clinical development
of ONCR-177, including expectations regarding timing for reporting
data from the ongoing Phase 1 clinical trial; the success and
therapeutic potential of Oncorus’ dual-platform pipeline; and the
ability of Oncorus’ technology to meaningfully shift the standard
of care in oncology. The words “may,” “might,” “will,” “could,”
“would,” “should,” “expect,” “plan,” “anticipate,” “intend,”
“believe,” “expect,” “estimate,” “seek,” :”predict,” “future,”
“project,” “potential,” “continue,” “target” and similar words or
expressions are intended to identify forward-looking statements,
although not all forward-looking statements contain these
identifying words. Any forward-looking statements in this press
release are based on management's current expectations and beliefs
and are subject to a number of risks, uncertainties and important
factors that may cause actual events or results to differ
materially from those expressed or implied by any forward-looking
statements contained in this press release, including, without
limitation, risks associated with: Oncorus’ ability to successfully
demonstrate the safety, tolerability and efficacy of its product
candidates and obtain regulatory approval thereof; Oncorus’ ability
to obtain the requisite components for its product candidates
manufactured in accordance with regulatory requirements; the impact
of COVID-19 on Oncorus’ operations and the timing and anticipated
results of its ongoing and planned clinical trials; the risk that
the results of preclinical studies and clinical trials may not be
predictive of future results in connection with future clinical
trials; the expansion of Oncorus’ in-house manufacturing
capabilities; the adequacy of Oncorus’ existing capital resources
and availability of financing on commercially reasonable terms; the
accuracy of the Oncorus’ estimates regarding expenses, future
revenue, capital requirements and needs for additional financing;
and Oncorus’ ability to obtain, maintain and protect its
intellectual property. These and other risks and uncertainties are
described in greater detail in the section entitled "Risk Factors"
in Oncorus’ Annual Report on Form 10-K for the year ended December
31, 2020, filed with the Securities and Exchange Commission on
March 10, 2021, as well as discussions of potential risks,
uncertainties, and other important factors in the other filings
that Oncorus makes with the Securities and Exchange Commission from
time to time. These documents are available under the “SEC filings”
page of the Investors section of Oncorus’ website at
http://investors.oncorus.com. Any forward-looking statements
represent Oncorus’ views only as of the date of this press release
and should not be relied upon as representing its views as of any
subsequent date. Oncorus explicitly disclaims any obligation to
update any forward-looking statements, whether as a result of new
information, future events or otherwise, except as required by law.
No representations or warranties (expressed or implied) are made
about the accuracy of any such forward-looking
statements.Investor Contact:Stern Investor
Relations Julie SeidelJulie.seidel@sternir.com
Oncorus (NASDAQ:ONCR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Oncorus (NASDAQ:ONCR)
Historical Stock Chart
From Jul 2023 to Jul 2024